Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 16,51 € (+83,44%). La mediana è 16,81 € (+86,78%).
| Acquista |
29 |
| Mantieni |
7 |
| Vendi |
3 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
ARK Invest expands position in Intellia Therapeutics and reduces Brera holding
ARK Invest increased its position in Intellia Therapeutics by 89,284 shares worth about 1.09 million USD via the ETFs ARKK and ARKG. At the same time, ARK sold 4,156 shares of Brera Holdings for approximately 15,377 USD through ARKK, ARKW and ARKF. ARK also bought shares of the 3iQ Solana Staking ETF (4,021 shares, about 33,615 USD), reflecting a strategic focus on biotechnology and selective investments in crypto assets. » Altro su de.investing.com
Intellia Therapeutics receives FDA priority review for lonvo-z, stock rises
The FDA has formally accepted the Biologics License Application (BLA) for lonvoguran ziclumeran (lonvo-z) and granted a priority review; the PDUFA date is March 10, 2027. A decision by an advisory committee is not currently planned, reducing regulatory uncertainty. The filing is based on strong Phase 3 data from the HAELO study showing a median reduction in monthly HAE attacks of 87% and 62% of patients attack-free over six months. Analysts reaffirmed a "Market Outperform" rating with a $30.00 price target, creating a near-term catalyst for the stock. » Altro su de.investing.com
ARK increases stake in Intellia Therapeutics and reduces Brera positions
Cathie Wood’s ARK bought 39,548 shares of Intellia Therapeutics on September 3 via the ARKG ETF for about $504,632, continuing a series of increases started in the days before. At the same time, ARK sold a total of 10,853 shares of Brera Holdings across several ETFs for roughly $41,241, further trimming the position in recent days. The transactions reflect a strategic reallocation in favor of Intellia and a reduction of exposure to Brera. » Altro su de.investing.com
Intellia shows strong phase‑3 data for CRISPR gene therapy lonvo‑z against hereditary angioedema
Intellia presented phase‑3 data from the HAELO study showing lonvo‑z reduced the monthly rate of attacks requiring treatment between weeks 5 and 28 by 89% versus placebo (0.19 vs. 1.79). Moderate to severe attacks fell by 91% and quality of life improved substantially more than with placebo. Adverse events were mostly mild to moderate, and no serious events were reported in the treatment arm. Intellia has filed a rolling BLA with the FDA and expects approval and a U.S. launch in the first half of 2027, while the stock has recently fallen despite the data. » Altro su de.investing.com
Intellia share price falls after $180 million capital raise at steep discount
The Intellia share dropped more than 8% in premarket trading to $12.09 after the company placed roughly 16.7 million shares at $10.75 each. The offering was increased from an initial $150 million to $180 million and was conducted at an 18.6% discount to the closing price. Proceeds are intended to finance clinical development, the commercialization of lead programs, R&D of additional candidates, and potential acquisitions. » Altro su de.investing.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 6,32 Mln | 46,15% |
| Utile lordo | 6,32 Mln | 111,39% |
| Utile netto | -112,55 Mln | 30,36% |
| EBITDA | -112,01 Mln | 36,37% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 1,24 Mld € |
Numero di azioni | 140,36 Mln |
Massimo/minimo a 52 settimane | 16,79 € - 7,22 € |
| Dividendi | No |
Beta | 1,82 |
Rapporto P/E | -2,90 |
Rapporto PEG | -0,12 |
Rapporto P/B | 2,22 |
Rapporto P/S | 25,74 |
Profilo aziendale
Intellia Therapeutics, Inc., una società di genome editing, si concentra sullo sviluppo di terapie. I programmi in vivo dell'azienda includono NTLA-2001, che si trova nella Fase 1 di sperimentazione clinica per il trattamento dell'amiloidosi da transtiretina; e NTLA-2002 per il trattamento dell'angioedema ereditario, oltre ad altri programmi focalizzati sul fegato, che comprendono emofilia A ed emofilia B, iperossaluria di tipo 1 e deficit di alfa-1 antitripsina. La sua pipeline ex vivo comprende NTLA-5001 per il trattamento della leucemia mieloide acuta; e programmi proprietari focalizzati sullo sviluppo di terapie cellulari ingegnerizzate per trattare diversi disturbi oncologici e autoimmuni. Inoltre, offre strumenti che comprendono il sistema Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9). Intellia Therapeutics, Inc. ha accordi di licenza e collaborazione con Novartis Institutes for BioMedical Research, Inc. per ingegnerizzare cellule staminali ematopoietiche per il trattamento dell'anemia falciforme; Regeneron Pharmaceuticals, Inc. per co-sviluppare potenziali prodotti per il trattamento di emofilia A ed emofilia B; Ospedale San Raffaele; e una collaborazione strategica con SparingVision SAS per sviluppare nuove terapie genomiche che utilizzano la tecnologia CRISPR/Cas9 per il trattamento di malattie oculari. La società era precedentemente nota come AZRN, Inc. Intellia Therapeutics, Inc. è stata costituita nel 2014 e ha sede a Cambridge, Massachusetts.
| Nome | Intellia Therapeutics |
| CEO | John Leonard |
| Sede centrale | Cambridge,
ma Stati Uniti |
| Sito web | |
| Settore | Sanità |
| Industria | Strumenti e servizi per le scienze della vita |
| Quotazione in borsa | 06/05/2016 |
| Dipendenti | 377 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | NTLA |
London Stock Exchange | 0JBU.L |
Frankfurt | 38I.F |
Düsseldorf | 38I.DU |
London | 0JBU.L |
SIX | 38I.SW |
München | 38I.MU |